Research

Nutrition and Neurodevelopment Activity

Nutrition and Infant Neurodevelopment

Nutrition has profound impact on neurodevelopment, but the mechanisms are only partly understood. In collaboration with other researchers at the Fetal-Neonatal Neuroimaging Developmental Science Center, we are studying the connections between maternal diet, breastmilk contents, infant brain development and child neurodevelopment. We also have a pilot study on the trajectory of infant develop the important skill of oral feeding with the goal of improving diagnosis and personalized care through quantitative EMG assessment of infant feeding, advanced computational analytics, and identifying biomarkers of neonatal outcomes.

Neurodevelopment FreeSurfer

Modifiers of Neurodevelopment among Patients with Congenital Heart Disease

Congenital heart disease (CHD) is the most common severe malformation. As improvements in medical and surgical management have led to increased survival, patients with congenital heart disease face additional lifelong health risks. Neurodevelopmental delay or impairment is the most common extracardiac complication of CHD. To better understand the mechanisms of neurodevelopmental risk in patients with CHD, we have recently participated a clinical trial that collected genetic, clinical, and neuropsychological testing data. Ongoing projects include further analysis of that trial data, and local pilot studies.

Gene Discovery Data

Gene Discovery in Congenital Heart Disease

We study the genetics of congenital heart disease with the goal of improving diagnosis and personalized care through gene discovery, functional analysis of patient variants, and identifying biomarkers of neonatal outcomes. Approaches include computational biology projects, cell culture projects, and multi-omic analysis of patient samples.

Publications

  • Sierant, M. C., Jin, S. C., Bilguvar, K., Morton, S. U., Dong, W., Jiang, W., Lu, Z., Li, B., López-Giráldez, F., Tikhonova, I., Zeng, X., Lu, Q., Choi, J., Zhang, J., Nelson-Williams, C., Knight, J. R., Zhao, H., Cao, J., Mane, S., … Lifton, R. P. (2025). Genomic analysis of 11,555 probands identifies 60 dominant congenital heart disease genes.. Proceedings of the National Academy of Sciences of the United States of America, 122(13), e2420343122. https://doi.org/10.1073/pnas.2420343122 (Original work published 2025)

    Congenital heart disease (CHD) is a leading cause of infant mortality. We analyzed de novo mutations (DNMs) and very rare transmitted/unphased damaging variants in 248 prespecified genes in 11,555 CHD probands. The results identified 60 genes with a significant burden of heterozygous damaging variants. Variants in these genes accounted for CHD in 10.1% of probands with similar contributions from de novo and transmitted variants in parent-offspring trios that showed incomplete penetrance. DNMs in these genes accounted for 58% of the signal from DNMs. Thirty-three genes were linked to a single CHD subtype while 12 genes were associated with 2 to 4 subtypes. Seven genes were only associated with isolated CHD, while 37 were associated with 1 or more extracardiac abnormalities. Genes selectively expressed in the cardiomyocyte lineage were associated with isolated CHD, while those widely expressed in the brain were also associated with neurodevelopmental delay (NDD). Missense variants introducing or removing cysteines in epidermal growth factor (EGF)-like domains of NOTCH1 were enriched in tetralogy of Fallot and conotruncal defects, unlike the broader CHD spectrum seen with loss of function variants. Transmitted damaging missense variants in MYH6 were enriched in multiple CHD phenotypes and account for  1% of all probands. Probands with characteristic mutations causing syndromic CHD were frequently not diagnosed clinically, often due to missing cardinal phenotypes. CHD genes that were positively or negatively associated with development of NDD suggest clinical value of genetic testing. These findings expand the understanding of CHD genetics and support the use of molecular diagnostics in CHD.

  • Kwon, H., Son, S., Morton, S. U., Wypij, D., Cleveland, J., Rollins, C. K., Huang, H., Goldmuntz, E., Panigrahy, A., Thomas, N. H., Chung, W. K., Anagnostou, E., Norris-Brilliant, A., Gelb, B. D., McQuillen, P., Porter, G. A., Tristani-Firouzi, M., Russell, M. W., Roberts, A. E., … Im, K. (2025). Graph-based prototype inverse-projection for identifying cortical sulcal pattern abnormalities in congenital heart disease.. Medical Image Analysis, 102, 103538. https://doi.org/10.1016/j.media.2025.103538 (Original work published 2025)

    Examining the altered arrangement and patterning of sulcal folds offers insights into the mechanisms of neurodevelopmental differences in psychiatric and neurological disorders. Previous sulcal pattern analysis used spectral graph matching of sulcal pit-based graph structures to assess deviations from normative sulcal patterns. However, challenges exist, including the absence of a standard criterion for defining a typical reference set, time-consuming cost of graph matching, user-defined feature weight sets, and assumptions about uniform node distribution. We developed a deep learning-based sulcal pattern analysis to address these challenges by adapting prototype-based graph neural networks to sulcal pattern graphs. Additionally, we proposed a prototype inverse-projection for better interpretability. Unlike other prototype-based models, our approach inversely projects prototypes onto individual node representations to calculate the inverse-projection weights, enabling efficient visualization of prototypes and focusing the model on selective regions. We evaluated our method through a classification task between healthy controls (n = 174, age = 15.4 ±1.9 [mean ± standard deviation, years]) and patients with congenital heart disease (n = 345, age = 15.8 ±4.7) from four cohort studies and a public dataset. Our approach demonstrated superior classification performance compared to other state-of-the-art models, supported by extensive ablative studies. Furthermore, we visualized and examined the learned prototypes to enhance understanding. We believe our method has the potential to be a sensitive and understandable tool for sulcal pattern analysis.

  • Dong, W., Jin, S. C., Sierant, M. C., Lu, Z., Li, B., Lu, Q., Morton, S. U., Zhang, J., López-Giráldez, F., Nelson-Williams, C., Knight, J. R., Zhao, H., Cao, J., Mane, S., Gruber, P. J., Lek, M., Goldmuntz, E., Deanfield, J., Giardini, A., … Brueckner, M. (2025). Recessive genetic contribution to congenital heart disease in 5,424 probands.. Proceedings of the National Academy of Sciences of the United States of America, 122(10), e2419992122. https://doi.org/10.1073/pnas.2419992122 (Original work published 2025)

    Variants with large effect contribute to congenital heart disease (CHD). To date, recessive genotypes (RGs) have commonly been implicated through anecdotal ascertainment of consanguineous families and candidate gene-based analysis; the recessive contribution to the broad range of CHD phenotypes has been limited. We analyzed whole exome sequences of 5,424 CHD probands. Rare damaging RGs were estimated to contribute to at least 2.2% of CHD, with greater enrichment among laterality phenotypes (5.4%) versus other subsets (1.4%). Among 108 curated human recessive CHD genes, there were 66 RGs, with 54 in 11 genes with >1 RG, 12 genes with 1 RG, and 85 genes with zero. RGs were more prevalent among offspring of consanguineous union (4.7%, 32/675) than among nonconsanguineous probands (0.7%, 34/4749). Founder variants in GDF1 and PLD1 accounted for 74% of the contribution of RGs among 410 Ashkenazi Jewish probands. We identified genome-wide significant enrichment of RGs in C1orf127, encoding a likely secreted protein expressed in embryonic mouse notochord and associated with laterality defects. Single-cell transcriptomes from gastrulation-stage mouse embryos revealed enrichment of RGs in genes highly expressed in the cardiomyocyte lineage, including contractility-related genes MYH6, UNC45B, MYO18B, and MYBPC3 in probands with left-sided CHD, consistent with abnormal contractile function contributing to these malformations. Genes with significant RG burden account for 1.3% of probands, more than half the inferred total. These results reveal the recessive contribution to CHD, and indicate that many genes remain to be discovered, with each likely accounting for a very small fraction of the total.

  • Ward, T., Morton, S. U., Venturini, G., Tai, W., Jang, M. Y., Gorham, J., Delaughter, D., Wasson, L. K., Khazal, Z., Homsy, J., Gelb, B. D., Chung, W. K., Bruneau, B. G., Brueckner, M., Tristani-Firouzi, M., DePalma, S. R., Seidman, C., & Seidman, J. G. (2025). Modeling SMAD2 Mutations in Induced Pluripotent Stem Cells Provides Insights Into Cardiovascular Disease Pathogenesis.. Journal of the American Heart Association, e036860. https://doi.org/10.1161/JAHA.124.036860 (Original work published 2025)

    BACKGROUND: SMAD2 is a coregulator that binds a variety of transcription factors in human development. Heterozygous SMAD2 loss-of-function and missense variants are identified in patients with congenital heart disease (CHD) or arterial aneurysms. Mechanisms that cause distinct cardiovascular phenotypes remain unknown. We aimed to define transcriptional and epigenetic effects of SMAD2 variants and their role in CHD. We also assessed the function of SMAD2 missense variants of uncertain significance.

    METHODS AND RESULTS: Rare SMAD2 variants (minor allele frequency ≤10-5) were identified in exome sequencing of 11 336 participants with CHD. We constructed isogenic induced pluripotent stem cells with heterozygous or homozygous loss-of-function and missense SMAD2 variants identified in CHD probands. Wild-type and mutant induced pluripotent stem cells were analyzed using bulk RNA sequencing, chromatin accessibility (Assay for Transposase-Accessible Chromatin With Sequencing), and integrated with published SMAD2/3 chromatin immunoprecipitation data. Cardiomyocyte differentiation and contractility were evaluated. Thirty participants with CHD had heterozygous loss-of-function or missense SMAD2 variants. SMAD2 haploinsufficiency altered chromatin accessibility at promoters and dysregulated expression of 385 SMAD regulated genes, including 10 CHD-associated genes. Motifs enriched in differential Assay for Transposase-Accessible Chromatin peaks predicted that SMAD2 haploinsufficiency disrupts interactions with transcription factors NANOG (homeobox protein NANOG), ETS, TEAD3/4 (transcriptional enhanced associate domain 3/4), CREB1 (cAMP response element binding protein 1), and AP1 (activator protein 1). Compared with SMAD2-haploinsufficient cells, induced pluripotent stem cells with R114C or W274C variants exhibited distinct and shared chromatin accessibility and transcription factor binding changes.

    CONCLUSIONS: SMAD2 haploinsufficiency disrupts transcription factor binding and chromatin interactions critical for cardiovascular development. Differences between the molecular consequences of loss-of-function and missense variants likely contribute to phenotypic heterogeneity. These findings indicate opportunities for molecular analyses to improve reclassification of SMAD2 variants of uncertain clinical significance.